Tuebingen, Germany and Houston, Texas, September 29, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in […]
Non-dilutive committed capital extends cash runway into at least 2024Facility strengthens balance sheet through anticipated commercial launches of Axsome’s two […]